• Publications
  • Influence
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Background Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selectiveExpand
  • 574
  • 22
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
BACKGROUND BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown antitumour activity inExpand
  • 260
  • 19
  • PDF
Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer
There is an urgent need for blood-based, noninvasive molecular tests to assist in the detection and diagnosis of cancers in a cost-effective manner at an early stage, when curative interventions areExpand
  • 229
  • 5
Reproductive Factors, Hormone Use, and Risk for Lung Cancer in Postmenopausal Women, the Nurses' Health Study
Background: There is increasing evidence suggesting that female hormones may play a significant role in lung cancer development. We evaluated the associations between reproductive factors, exogenousExpand
  • 68
  • 2
Non‐steroidal anti‐inflammatory drugs and cancer risk in women: Results from the Women's Health Initiative
The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) has been associated with reduced risks of cancers at several sites in some studies; however, we recently reported no association betweenExpand
  • 37
  • 2
Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).
9008Background: RET fusions are targetable oncogenic drivers in up to 2% of NSCLC, yet no selective RET inhibitors are approved. BLU-667 is an investigational highly potent and selective RET inhibi...
  • 39
  • 2
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer
8509Background: T-DM1 is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer. We report primary results from a fully enrolled, ongoing phase 2 study (NCT02289833) of pts ...
  • 24
  • 2
Estrogen Signaling in Lung Cancer: An Opportunity for Novel Therapy
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biologicalExpand
  • 25
  • 2
  • PDF
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication.
®e report an epidermal growth factor receptor (EGFR) tandem kinase domain duplication (TKD-EGFR) mutation in a non–small-cell lung cancer (NSCLC) patient who had a greater than 10-year response toExpand
  • 15
  • 2
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
Brain metastases (BM) occur frequently in many cancers, particularly non-small cell lung cancer (NSCLC), breast cancer, and melanoma. The development of BM is associated with poor prognosis and hasExpand
  • 71
  • 1